Table 1. Anti-HBs antibody seropositivity rates and geometric mean concentrations from primary vaccination at infancy until year 20 for pooled groups with boosted and unboosted at year 5 (Long-term ATP cohort for immunogenicity).
| |
N |
S+ |
≥ 10 mIU/ml |
GMC* mIU/ml |
|||
|---|---|---|---|---|---|---|---|
| Time Point (Year) |
|
% |
95% CI |
% |
95% CI |
mIU/ml |
95% CI |
| Unboosted group | |||||||
| 1 |
60 |
100 |
(94.0,100) |
100 |
(94.0,100) |
265.3 |
(179.9,391.3) |
| 2 |
55 |
100 |
(93.5,100) |
96.4 |
(87.5,99.6) |
96.6 |
(65.7,142.2) |
| 3 |
51 |
98.0 |
(89.6,100) |
92.2 |
(81.1,97.8) |
99.4 |
(69.8,141.7) |
| 4 |
46 |
97.8 |
(88.5,99.9) |
91.3 |
(79.2,97.6) |
64.3 |
(44.9,91.9) |
| 5 |
44 |
97.7 |
(88.0,99.9) |
86.4 |
(72.6,94.8) |
42.0 |
(27.9,63.2) |
| 6 |
40 |
97.5 |
(86.8,99.9) |
75.0 |
(58.8,87.3) |
33.3 |
(20.6,53.7) |
| 7 |
41 |
97.6 |
(87.1,99.9) |
70.7 |
(54.5,83.9) |
27.0 |
(17.5,41.8) |
| 8 |
34 |
97.1 |
(84.7,99.9) |
67.6 |
(49.5,82.6) |
22.5 |
(14.1,35.7) |
| 9^ |
4 |
100 |
(39.8,100) |
100 |
(39.8,100) |
59.3 |
(46.9,74.8) |
| 10 |
27 |
96.3 |
(81.0,99.9) |
66.7 |
(46.0,83.5) |
25.0 |
(13.9,45.0) |
| 11 |
33 |
72.7 |
(54.5,86.7) |
57.6 |
(39.2,74.5) |
32.2 |
(18.6,55.7) |
| 12 |
31 |
67.7 |
(48.6,83.3) |
54.8 |
(36.0,72.7) |
36.8 |
(18.4,73.6) |
| 13 |
33 |
66.7 |
(48.2,82.0) |
45.5 |
(28.1,63.6) |
26.2 |
(14.1,48.5) |
| 14 |
33 |
63.6 |
(45.1,79.6) |
45.5 |
(28.1,63.6) |
25.5 |
(13.4,48.6) |
| 15 |
32 |
56.3 |
(37.7,73.6) |
34.4 |
(18.6,53.2) |
20.0 |
(11.3,35.5) |
| 16 |
29 |
69.0 |
(49.2,84.7) |
48.3 |
(29.4,67.5) |
18.4 |
(10.8,31.5) |
| 17 |
26 |
65.4 |
(44.3,82.8) |
26.9 |
(11.6,47.8) |
12.6 |
(6.9,22.8) |
| 18 |
27 |
55.6 |
(35.3,74.5) |
37.0 |
(19.4,57.6) |
17.3 |
(10.2,29.2) |
| 19 |
23 |
65.2 |
(42.7,83.6) |
39.1 |
(19.7,61.5) |
14.1 |
(7.6,26.1) |
| 20 | 25 | 76.0 | (54.9,90.6) | 44.0 | (24.4,65.1) | 15.3 | (9.3,25.4) |
| Boosted group | |||||||
|---|---|---|---|---|---|---|---|
| 1 |
43 |
100 |
(91.8,100) |
100 |
(91.8,100) |
195.8 |
(120.2,319.0) |
| 2 |
43 |
100 |
(91.8,100) |
93.0 |
(80.9,98.5) |
67.2 |
(42.7,106.0) |
| 3 |
43 |
100 |
(91.8,100) |
86.0 |
(72.1,94.7) |
65.8 |
(40.4,107.3) |
| 4 |
41 |
97.6 |
(87.1,99.9) |
82.9 |
(67.9,92.8) |
62.3 |
(37.0,104.8) |
| 5 |
43 |
97.7 |
(87.7,99.9) |
79.1 |
(64.0,90.0) |
40.0 |
(24.6,65.1) |
| 5* |
41 |
100 |
(91.4,100) |
100 |
(91.4,100) |
3375.9 |
(1722.0,6618.5) |
| 6 |
38 |
100 |
(90.7,100) |
92.1 |
(78.6,98.3) |
568.3 |
(269.6,1198.1) |
| 7 |
37 |
97.3 |
(85.8,99.9) |
89.2 |
(74.6,97.0) |
471.5 |
(219.1,1014.8) |
| 8 |
32 |
100 |
(89.1,100) |
93.8 |
(79.2,99.2) |
198.7 |
(99.5,396.6) |
| 9^ |
6 |
100 |
(54.1,100) |
83.3 |
(35.9,99.6) |
603.1 |
(29.9,12171.4) |
| 10 |
27 |
100 |
(87.2,100) |
92.6 |
(75.7,99.1) |
144.3 |
(66.3,313.8) |
| 11 |
34 |
97.1 |
(84.7,99.9) |
94.1 |
(80.3,99.3) |
288.2 |
(146.0,568.8) |
| 12 |
31 |
96.8 |
(83.3,99.9) |
96.8 |
(83.3,99.9) |
282.1 |
(145.9,545.6) |
| 13 |
32 |
93.8 |
(79.2,99.2) |
87.5 |
(71.0,96.5) |
234.1 |
(122.6,447.0) |
| 14 |
32 |
96.9 |
(83.8,99.9) |
87.5 |
(71.0,96.5) |
167.5 |
(83.4,336.6) |
| 15 |
29 |
93.1 |
(77.2,99.2) |
86.2 |
(68.3,96.1) |
127.0 |
(63.3,254.9) |
| 16 |
27 |
100 |
(87.2,100) |
88.9 |
(70.8,97.6) |
125.7 |
(58.9,268.5) |
| 17 |
28 |
92.9 |
(76.5,99.1) |
85.7 |
(67.3,96.0) |
104.6 |
(50.0,218.9) |
| 18 |
24 |
100 |
(85.8,100) |
83.3 |
(62.6,95.3) |
70.4 |
(32.2,153.8) |
| 19 |
22 |
95.5 |
(77.2,99.9) |
81.8 |
(59.7,94.8) |
95.9 |
(40.9,224.5) |
| 20 | 19 | 94.7 | (74.0,99.9) | 84.2 | (60.4,96.6) | 108.7 | (46.2,255.9) |
Boosted: subjects who received booster dose at year 5 (month 60). Unboosted: subjects who did not receive booster dose at year 5 (month 60)
*
, year 5 (one month post-administration of booster dose); ^, At year 9, the sample size was low since fewer subjects were loaded onto the database in both boosted and unboosted groups; N, number of subjects with available results; n/%, number/percentage of seropositive subjects or subjects with anti-HBs antibody concentrations ≥ 10 mIU/ml; GMC*, Geometric mean concentrations calculated on seropositive subjects; S+, Seropositivity defined as anti-HBs antibody concentrations ≥ 1.0 mIU/ml up to year 10 and ≥ 3.3 mIU/ml from year 11 onwards